跳至主要内容
临床试验/NCT06794333
NCT06794333已完成不适用

Comparative Efficacy of Trans-Perineal Laser Ablation Vs Water Vapor Ablation for Benign Prostatic Hyperplasia: a Single Center Randomized Controlled Trial

University of Pisa2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2024年1月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
2
主要终点
Improvement of Urodynamics parameters after 3 and 12 Months of Follow up

研究概览

简要总结

The primary aim of this clinical trial is to determine whether one of the two methods under investigation, TPLA or WVA, is superior in the treatment of BPH. Additionally, as a secondary objective, the study seeks to evaluate the potential superiority of one method over the other concerning the sexual parameters of treated participants, assessed using the International Index of Erectile Function 5 (IIEF5) and the Male Sexual Health Questionnaire - Ejaculatory Dysfunction (MSHQ-EJ).

The researchers will compare the two methods under investigation (TPLA and WVA) to assess the potential superiority of one over the other.

Participants will:

  • be randomized 1:1 between the two techniques and will undergo treatment at time 0;
  • undergo follow-up including uroflowmetry and assessment of the International Prostate Symptoms Score (IPSS), IIEF5, and MSHQ-EJ questionnaires at 3, 6, and 12 months.

详细描述

Therapeutic options for the treatment of benign prostatic hyperplasia (BPH) encompass a wide range of both pharmacological and surgical approaches. BPH is an age-related condition that increasingly affects relatively younger individuals, starting from the age of 50.

Pharmacological therapy primarily involves medications that can alleviate symptoms but do not cure or lead to a regression of the prostate gland enlargement over time.

Surgical therapy aims to reduce the degree of obstruction, and in most cases, it can result in significant alterations in sexual function, such as inducing retrograde ejaculation or causing erectile dysfunction. These side effects are more common with the use of classical treatment methods, whose clinical value is widely recognized and confirmed by clinical evidence reported in international guidelines (EAU Guidelines, 2021 edition).

The classical surgical treatment methods include the removal of the adenoma (benign hyperplastic part of the prostate gland) through open surgery, transurethral resection (TURP), laser ablation with en bloc removal (holmium and thulium lasers), or direct cavitation (green light laser). These classical methods typically require hospital admission with a stay of three days or more, depending on the extent of postoperative bleeding and the risk of post-surgical obstructive complications (bladder clots).

On the other hand, some minimally invasive and innovative methods can reduce the symptoms caused by the disease while preserving the patient's sexual function. These techniques also allow for treatment without hospitalization or, at most, in a outpatients setting, utilizing local anesthesia or sedation and presenting a low risk of bleeding or other complications. Specifically, the minimally invasive technologies aim for thermal ablation of the hyperplastic tissue without cavitation. This approach results in longer healing times and clinical improvement, as they are dependent on cellular apoptosis, tissue necrosis, and spontaneous gland remodeling, which occur in the months following treatment, thus not producing immediate visible or effective results.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • PSA levels under 4 ng/ml (if PSA is over 4 ng/ml, a multiparametric prostate magnetic resonance will be performed; if a lesion with a PIRADS score over 2 is detected, a prostate biopsy will be conducted);
  • Post void residual (PVR) over 50 ml;
  • Maximum flow (Qmax) under 15 ml/s;
  • IPSS score over 7;
  • The possibility of undergoing transrectal ultrasound to assess the size of the prostate and prostate adenoma;
  • Negative urinary culture.

排除标准

  • Diabetes;
  • Overactive or Underachieve bladder;
  • Contraindications for performing MRI or prostate biopsy in cases where PSA is over 4 ng/ml;
  • Intolerance to transrectal ultrasound;
  • Intolerance or allergy to local anesthetics.

结局指标

主要结局

Improvement of Urodynamics parameters after 3 and 12 Months of Follow up

时间窗: up to 12 months

After 3,6 and 12 months of follow-up, uroflowmetry will be conducted to assess improvements in urinary maximum flow (Qmax: ml/sec) and average flow (Qmed: ml/sec). Milliliters and seconds will be combined to calculate and report Qmax and Qmed.

Improvement in post voided residual

时间窗: up to 12 months

After 3,6 and 12 months of follow-up, uroflowmetry will be conducted to assess improvements post voided residual (PVR: ml). Milliliters will be used to report PVR.

Improvement in International Prostate Symptoms Score

时间窗: up to 12 months

After 3,6 and 12 months of follow-up International Prostate Symptom Score (IPSS) questionnaire will be administered to all participants to evaluate changes in subjective symptoms and quality of life (Lower IPSS values indicate an improvement in the symptoms reported by the patient). The IPSS ranges from 0 to 35, with scores interpreted as follows: 0-7 indicates mild symptoms, 8-19 indicates moderate symptoms, and 20-35 indicates severe symptoms.

次要结局

  • Postoperative complications(up to 3 months)
  • Prostate Specific Antigen (PSA) value(up to 12 months)
  • sexual outcomes(up to 12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ALESSANDRO ZUCCHI

Professor

University of Pisa

研究点 (2)

Loading locations...

相似试验